Loading
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Previous close
$1.11
+$0.06 · +5.71%
Regular session · ET · Market data may be delayed.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Day range
Current $1.11
52-week range
Current $1.11
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
90
Deep Value
Sentiment
55
Mixed
Risk
75
High Risk
Momentum
28
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Day range
Current $1.11
52-week range
Current $1.11
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 80.28M USD | 69.3M USD | 58.45M USD | 41.42M USD | 29.46M USD |
| Cost of goods sold | 25.93M USD | 22.81M USD | 18.34M USD | 14.37M USD | 10.65M USD |
| Gross profit | 54.34M USD | 46.49M USD | 40.11M USD | 27.04M USD | 18.81M USD |
| Research and development | 9.22M USD | 8.81M USD | 9.62M USD | 8.94M USD | 6.74M USD |
| Selling, general, and administrative | 78.88M USD | 79.37M USD | 74.57M USD | 57.11M USD | 41.52M USD |
| Operating expenses | 88.1M USD | 80.6M USD | 84.19M USD | 66.05M USD | 48.26M USD |
| Interest expense | 5.25M USD | 5.29M USD | 5.22M USD | 4.05M USD | 3.6M USD |
| Depreciation and amortization | 1.01M USD | 1.01M USD | 808K USD | 1.19M USD | 535K USD |
| Operating income | −33.76M USD | −34.12M USD | −44.08M USD | −39.01M USD | −29.45M USD |
| Net income | −38.83M USD | −37.84M USD | −46.66M USD | −44.3M USD | −33.28M USD |
Company facts updated Oct 10, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$2.00
80.18% upsideFunds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
